Royal Bank Of Canada Nex Immune, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.2 - $0.3 $9 - $14	48 Added 9.41%	558 $0
Q2 2023 Aug 14, 2023	BUY	$0.26 - $0.47 $132 - $239	510 New	510 $0
Q3 2022 Nov 14, 2022	BUY	$0.6 - $17.5 $28 - $840	48 New	48 $0
Q2 2022 Aug 15, 2022	SELL	$1.61 - $4.68 $2,093 - $6,084	-1,300 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.79 - $4.65 $7,262 - $18,865	-4,057 Reduced 75.73%	1,300 $6,000
Q4 2021 Feb 14, 2022	BUY	$4.11 - $15.13 $12,017 - $44,240	2,924 Added 120.18%	5,357 $25,000
Q3 2021 Nov 15, 2021	BUY	$10.32 - $16.9 $18,121 - $29,676	1,756 Added 259.38%	2,433 $36,000
Q2 2021 Aug 16, 2021	BUY	$14.98 - $23.89 $10,141 - $16,173	677 New	677 $12,000

Ticker NEXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,155,600
Market Cap $5.07M
Description
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's pr...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.